

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCAL United States Patent and Trademark Office (Victoria) (Victori

APPLICATION NO	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKETNO	CONFIRMATION NO	
09 905,744	07 13 2001	Brian Paul Chadwick	28110-36120 ₃ X	6794	
1717	\$80 [0.01.2002				
MARSHALL, GERSTEIN & BORUN 6300 SEARS TOWER 233 SOUTH WACKER			EXAMINER		
			DECLOUX, AMY M		
CHICAGO, IL 60606-6357			ARTUNII	PAPER NUMBER	
			1644	()	
			DATE MAILED TO 01 2002	X	

Please find below and or attached an Office communication concerning this application or proceeding.

		Application No.	A	pplicant(s)	
Office Action Summary		09/905,744			۸۲.
		Examiner		rt Unit	
	·	Amy M. DeCloux		644	
	The MAILING DATE of this communication app				dress
Period fo				·	
THE N - Exter after - If the - If NO - Failui - Any r	ORTENED STATUTORY PERIOD FOR REPLY MAILING DATE OF THIS COMMUNICATION. Insigns of time may be available under the provisions of 37 CFR 1.1 SIX (6) MONTHS from the mailing date of this communication of period for reply specified above is less than thirty (30) days, a reply operiod for reply is specified above, the maximum statutory period were to reply within the set or extended period for reply will, by statute reply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	36(a) In no event, howevery within the statutory minim will apply and will expire SD, cause the application to b	er, may a reply be timely um of thirty (30) days wi K (6) MONTHS from the ecome ABANDONED (filed If be considered time mailing date of this case to S.C. § 133)	
1)	Responsive to communication(s) filed on 02 h	May 2002 .			
2a)		is action is non-fina	al.		
3)	Since this application is in condition for allows closed in accordance with the practice under	•			ne merits is
· ·	on of Claims				
	Claim(s) 19-24 is/are pending in the application				
	4a) Of the above claim(s) is/are withdraw	wn from considerat	ion.		
	Claim(s) is/are allowed.				
	Claim(s) is/are rejected.				
	Claim(s) is/are objected to.				
	Claim(s) <u>19-24</u> are subject to restriction and/or on Papers	r election requireme	ent.		
	The specification is objected to by the Examine	r			
·	The drawing(s) filed on is/are: a)☐ accept		I to by the Evami	nor	
10)[Applicant may not request that any objection to the		-		
11)	The proposed drawing correction filed on		•		
,	If approved, corrected drawings are required in re			•	
12) 🗌 -	The oath or declaration is objected to by the Ex	aminer.			
Priority u	ınder 35 U.S.C. §§ 119 and 120				
13)	Acknowledgment is made of a claim for foreign	n priority under 35 t	J.S.C. § 119(a)-(d) or (f).	
a)[☐ All b)☐ Some * c)☐ None of:				
	1. Certified copies of the priority document	s have been receiv	ed.		
	2. Certified copies of the priority document	s have been receiv	ed in Application	No	
* S	3. Copies of the certified copies of the prior application from the International Buse the attached detailed Office action for a list	reau (PCT Rule 17	.2(a)).	in this National	Stage
14) 🗌 A	Acknowledgment is made of a claim for domesti	ic priority under 35	U.S.C. § 119(e) (to a provisiona	ıl application).
) The translation of the foreign language pro Acknowledgment is made of a claim for domest	• • •			
Attachmen		•			
2) Notic	tie of References Cited (PTO-892) tie of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449) Paper No(s) _	5) 🔲 N	nterview Summary (F lotice of Informal Pat hther:		

Application/Control Number: 09/905,744

Art Unit: 1644

DETAILED ACTION

Election/Restrictions

- 1. This application contains claims directed to the following patentably distinct species of the claimed invention: An isolated polypeptide having phosphohydrolase activity comprising an enzymatically active fraction of SEQ ID NO:6 wherein said fragment comprises the species of amino acid residues 47-68, 123-138 167-187 or 193-214 of SEQ ID NO:6 as recited in claims 24. These species are distinct because each polypeptide fragment comprises a unique structure with distinct biochemical and biological functions.
- 2. Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claim 20 is generic.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

3. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Amy M. DeCloux whose telephone number is 703 306-5821. The examiner can normally be reached on M-F 8:00-5:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on 703 308-3973. The fax phone numbers for the organization where this application or proceeding is assigned are 703 305-3014 for regular communications and 703 872-9307 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703 308-0196.

Amy DeCloux, Ph.D., Patent Examiner, September 29, 2002 Patrick J. Nolan, Ph.D., Primary Patent Examiner,

Group 1640